Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

Press Releases

Month Year

Investor Alerts

Dec 31, 2018

Lipocine Announces Successful Ex Vivo Conversion Assessment of TLANDO™

Lipocine, Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced completion of a definitive phlebotomy study ("Phlebotomy Study") to assess the extent, if any, of clinically...
Dec 21, 2018

Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 results as part of the 2019 NASH-TAG Conference. The presentation...
Dec 20, 2018

Lipocine Announces LPCN 1144 MRI-PDFF Clinical Results Selected for Presentation at Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLD

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 clinical results as part of the Keystone Symposia on Integrated...
Nov 7, 2018

Lipocine Announces Financial and Operational Results for the Three and Nine Months Ended September 30, 2018

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and nine months ended September 30, 2018. Third Quarter and Recent Corporate...
Nov 5, 2018

Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the completion of enrollment in the proof-of-concept clinical study with LPCN 1144 to assess liver fat changes in...
Nov 1, 2018

Lipocine Announces Completion of Enrollment in Ambulatory Blood Pressure Study for TLANDO™

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the completion of enrollment in the ambulatory blood pressure ("ABPM") clinical study for TLANDO™, the Company's...
Oct 11, 2018

Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting® 2018

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 results as part of the late-breaker session of The Liver Meeting®...
Sep 25, 2018

Lipocine to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Ladenburg Thalmann...
Aug 7, 2018

Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2018

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2018. Second Quarter and Recent Corporate Highlights...
Aug 2, 2018

Lipocine to Present at the Canaccord Genuity 38th Annual Growth Conference

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Canaccord Genuity...
Jun 7, 2018

Lipocine Announces Dosing in Ambulatory Blood Pressure Study for TLANDO™

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced the dosing of the first subject in the ambulatory blood pressure ("ABPM") clinical study for TLANDO™, the...
May 9, 2018

Lipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug Administration

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from the United States Food and Drug Administration...
May 7, 2018

Lipocine Announces Financial and Operational Results for the First Quarter Ended March 31, 2018

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2018. First Quarter and Recent Corporate Highlights The...
Mar 21, 2018

Lipocine to Present at the 17th Annual Needham Healthcare Conference

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the 17th Annual Needham...
Mar 14, 2018

Lipocine to Present at the Oppenheimer 28th Annual Healthcare Conference

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Oppenheimer 28th...
Mar 12, 2018

Lipocine Announces Financial and Operational Results for the Fiscal Year Ended December 31, 2017

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2017. Fourth Quarter and Recent...
Mar 5, 2018

Lipocine to Present at the 30th Annual ROTH Conference

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and Chief Executive Officer, will provide a corporate overview at the...
Feb 16, 2018

Lipocine Announces Settlement of Securities Class Action Lawsuit

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that the Company and the other defendants have entered into a memorandum of understanding to settle the purported...
Feb 8, 2018

Lipocine Announces $10 Million Loan and Security Agreement with Silicon Valley Bank

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced the receipt of $10.0 million in January 2018 by means of a Loan and Security Agreement between the Company and its...
Feb 7, 2018

Lipocine to Present at the LEERINK Partners 7th Annual Global Healthcare Conference

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the LEERINK Partners 7th...
Jan 10, 2018

Lipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO™, Testosterone Replacement Therapy in Adult Males with Hypogonadism

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that the Bone, Reproductive and Urologic Drugs Advisory Committee ("BRUDAC") of the U.S. Food and Drug...
Nov 17, 2017

U.S. FDA Extends Review for TLANDO™; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged

SALT LAKE CITY, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration ("FDA") has extended the...
Nov 8, 2017

Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017

SALT LAKE CITY, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the three and nine months ended September...
Oct 18, 2017

FDA Advisory Committee Scheduled to Review TLANDO™ on January 10, 2018

SALT LAKE CITY, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration ("FDA") has scheduled the...
Sep 21, 2017

Lipocine Announces Motions Decision by USPTO in Interference Against Clarus

SALT LAKE CITY , Sept. 21, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Patent Trial and Appeal Board ("PTAB") of the United...
Sep 20, 2017

Lipocine Announces FDA Advisory Committee Meeting for TLANDO™

SALT LAKE CITY, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Bone, Reproductive and Urologic Drugs Advisory Committee ("
Sep 19, 2017

Lipocine to Present at the Ladenburg Thalmann 2017 Healthcare Conference

SALT LAKE CITY, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide...
Sep 5, 2017

Lipocine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

SALT LAKE CITY, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide...
Aug 14, 2017

Lipocine Announces FDA Acknowledgement of TLANDO™ ("LPCN 1021") NDA Resubmission; PDUFA Goal Date, February 8, 2018

SALT LAKE CITY, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration ("FDA") has acknowledged...
Aug 9, 2017

Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism

SALT LAKE CITY, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the resubmission of a New Drug Application ("NDA") for LPCN 1021,...
Aug 7, 2017

Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017

SALT LAKE CITY, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30,...
Aug 2, 2017

Lipocine to Present at the Canaccord Genuity 37th Annual Growth Conference

SALT LAKE CITY, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide...
Jun 26, 2017

Lipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth

SALT LAKE CITY, June 26, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has submitted a Special Protocol Assessment ("SPA")...
Jun 19, 2017

Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Dosing Validation and Dosing Flexibility Studies of LPCN 1021

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

SALT LAKE CITY, June 19, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Company will host a conference call and webcast today,...
Jun 19, 2017

Lipocine Validates "No Titration" Dosing Regimen With Positive Topline Efficacy Results for LPCN 1021, Oral Testosterone Candidate

LPCN 1021 achieved primary endpoints confirming the efficacy of twice daily oral administration

SALT LAKE CITY, June 19, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced results from both the Dosing Validation ("DV") and the Dosing...
Jun 15, 2017

Lipocine Announces Successful Completion of Food Effect Study for LPCN 1021, an Oral Testosterone Product Candidate

Consistent and predictable therapeutic levels of testosterone when administered with a meal

SALT LAKE CITY, June 15, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the successful completion of its labeling "food effect study" for...
Jun 2, 2017

Lipocine to Present at the Jefferies 2017 Healthcare Conference

SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, and Morgan...
May 8, 2017

Lipocine Announces Financial and Operational Results for the First Quarter 2017

SALT LAKE CITY, May 08, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2017....
Apr 24, 2017

Lipocine Completes Enrollment in the LPCN 1021 Fixed Dose Clinical Trials

Top-line data from the studies expected in June 2017

SALT LAKE CITY, April 24, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the completion of enrollment for both its dosing validation...
Mar 28, 2017

Lipocine to Present at 16th Annual Needham Healthcare Conference

SALT LAKE CITY, March 28, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
Mar 6, 2017

Lipocine to Present at 29th Annual ROTH Conference

SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
Mar 6, 2017

Lipocine Announces Financial and Operational Results for the Full Year of 2016

SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the full year ended...
Feb 15, 2017

Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer

SALT LAKE CITY, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company focused on developing innovative oral treatment alternatives for use in men's and...
Feb 14, 2017

Lipocine to Present at 27th Annual Oppenheimer Conference

SALT LAKE CITY, March 14, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
Jan 9, 2017

Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth

Critical Phase 3 study design input received from U.S. Food and Drug Administration ("FDA"): Agreed to a randomized open-label, two-arm clinical study to include a LPCN 1107 arm and a comparator...
Jan 5, 2017

Lipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate

SALT LAKE CITY, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced plans to initiate a dosing flexibility ("DF") study in addition...
Dec 5, 2016

Lipocine to Initiate Dosing Validation Study for LPCN 1021, Oral Testosterone Replacement Product Candidate

SALT LAKE CITY, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced it plans to initiate a dosing validation study after receiving...
Nov 8, 2016

Lipocine Announces Financial and Operational Results for the Third Quarter of 2016

SALT LAKE CITY, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended September...
Nov 7, 2016

Lipocine Announces Issuance of US Patent 9,480,690

SALT LAKE CITY, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today reported the United States Patent and Trademark Office ("USPTO") issued...
Oct 17, 2016

Lipocine Completes Post Action Meeting With FDA for LPCN 1021 New Drug Application

SALT LAKE CITY, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the completion of a Post Action meeting with the U.S. Food and...
Oct 7, 2016

Lipocine Wins Dismissal of Patent Infringement Lawsuit Related to LPCN 1021

SALT LAKE CITY, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that U.S. District Court in Delaware granted our motion to...
Sep 26, 2016

Lipocine Announces Positive Top-Line Phase 2b Study Results for LPCN 1111, a Next Generation Oral Testosterone Replacement Therapy

Once-daily dose identified for the pivotal Phase 3 study

SALT LAKE CITY, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today reported positive top-line results from a Phase 2b clinical study of LPCN...
Sep 20, 2016

Lipocine to Present at 2016 Ladenburg Thalmann Healthcare Conference

SALT LAKE CITY, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
Aug 9, 2016

Lipocine Announces Financial and Operational Results for the Second Quarter of 2016

SALT LAKE CITY, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended June 30,...
Aug 4, 2016

Lipocine to Present at 36th Annual Canaccord Genuity Growth Conference

SALT LAKE CITY, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
Jun 29, 2016

Lipocine Receives Complete Response Letter (CRL) for LPCN 1021 From U.S. Food and Drug Administration

SALT LAKE CITY, June 29, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has received a Complete Response Letter ("CRL") from the...
Jun 26, 2016

Lipocine Added to Russell 3000 and Russell Global Indexes

SALT LAKE CITY, June 27, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has been added to the Russell 3000® and Russell Global®...
May 9, 2016

Lipocine Announces Financial and Operational Results for the First Quarter of 2016

SALT LAKE CITY, May 09, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended March 31,...
May 2, 2016

Lipocine Announces the Presentation of Clinical Data for Oral Testosterone Replacement Therapy Product Candidate TLANDO™ ("LPCN 1021") at the 2016 American Urological Association Annual Meeting

SALT LAKE CITY, May 02, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for lead candidate TLANDO™ ("LPCN 1021"),...
Apr 6, 2016

Lipocine to Present at 15th Annual Needham & Company Healthcare Conference

SALT LAKE CITY, April 06, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
Mar 28, 2016

Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at the American Society of Andrology 41st Annual Conference

SALT LAKE CITY, March 28, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone...
Mar 10, 2016

Lipocine Announces Financial and Operational Results for the Full Year of 2015

SALT LAKE CITY, March 10, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2015....
Mar 8, 2016

Lipocine to Present at 28th Annual Roth Conference

SALT LAKE CITY, March 08, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
Feb 27, 2016

Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at ENDO 2016

SALT LAKE CITY, March 28, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone...
Feb 16, 2016

Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women

Relevant hydroxyprogesterone caproate levels achieved following oral administration

SALT LAKE CITY, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced top-line results from its multi-dose pharmacokinetic ("PK") dose...
Jan 4, 2016

Lipocine Announces First Patient Dosed in Phase 2B Clinical Study for LPCN 1111, a Novel Testosterone Replacement Therapy

SALT LAKE CITY, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the first patient has been dosed in its Phase 2b clinical...
Dec 6, 2015

Lipocine Appoints Dr. Jyrki Mattila as Chief Business Officer

SALT LAKE CITY, May 18, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the appointment of Jyrki Mattila, M.D., Ph.D., M.B.A to the newly...
Nov 23, 2015

Lipocine to Present at 27th Annual Piper Jaffray Healthcare Conference

SALT LAKE CITY, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
Nov 13, 2015

Lipocine Adopts Stockholder Rights Plan

SALT LAKE CITY, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that on November 12, 2015 its board of directors adopted a...
Nov 12, 2015

Lipocine Announces PDUFA Goal Date for LPCN 1021 NDA

SALT LAKE CITY, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has assigned a...
Nov 11, 2015

Lipocine Announces Presentation of LPCN 1021 Clinical Data at 21st Annual SMSNA Meeting

SALT LAKE CITY, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone product...
Oct 29, 2015

FDA Accepts for Filing Lipocine's New Drug Application for Its Oral Testosterone Replacement Product Candidate, LPCN 1021

SALT LAKE CITY, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has accepted...
Oct 12, 2015

Lipocine Announces Financial and Operational Results for the Third Quarter of 2015

SALT LAKE CITY, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2015, as...
Sep 28, 2015

Lipocine Announces First Subject Dosed in Multi-Dose PK Study for Its Oral Product Candidate for the Prevention of Pre-Term Birth

SALT LAKE CITY, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the first subject dosed in its multi-dose PK dose finding...
Sep 22, 2015

Lipocine to Present at Ladenburg Thalmann 2015 Healthcare Conference

SALT LAKE CITY, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
Aug 31, 2015

Lipocine Submits New Drug Application to FDA for Its Oral Testosterone Replacement Product Candidate, LPCN 1021

SALT LAKE CITY, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has submitted a 505(b)(2) New Drug Application ("NDA") to the
Aug 10, 2015

Lipocine Announces Financial and Operational Results for the Second Quarter of 2015

SALT LAKE CITY, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended June 30, 2015, as well as...
Aug 5, 2015

Lipocine to Present at 35th Annual Canaccord Genuity Growth Conference

SALT LAKE CITY, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
Jun 29, 2015

Lipocine's Oral Testosterone Well Tolerated in Phase 3 Study

LPCN 1021 was well tolerated during 52 weeks of dosing

SALT LAKE CITY, June 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced top-line 52-week safety results from its Study of Oral Androgen...
Jun 15, 2015

Lipocine to Present at the JMP Securities Life Sciences Conference

SALT LAKE CITY, June 16, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced today announced Mahesh Patel, President and CEO, and Morgan Brown,...
Jun 8, 2015

Lipocine Announces Development Plans for LPCN 1107

SALT LAKE CITY, June 8, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced its development plans for LPCN 1107, the company's oral...
Jun 2, 2015

Lipocine Receives FDA Orphan Drug Designation for LPCN 1107, an Oral Product Candidate for the Prevention of Preterm Birth

SALT LAKE CITY, June 2, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration ("FDA") has granted orphan...
May 11, 2015

Lipocine Announces Presentation of Additional LPCN 1021 Clinical Data at American Urological Association Annual Meeting

SALT LAKE CITY, May 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that additional data from its ongoing Study of Oral Androgen...
May 7, 2015

Lipocine Announces Financial and Operational Results for the First Quarter of 2015

SALT LAKE CITY, May 7, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2015, as well as...
Apr 30, 2015

Lipocine Announces Completion of LPCN 1021, Oral Testosterone, Phase 3 Clinical Trial

SALT LAKE CITY, April 30, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the completion of the last patient visit in the safety...
Apr 29, 2015

Lipocine Prices $30.2 Million Public Offering of Common Stock

SALT LAKE CITY, April 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has priced an underwritten public offering of 4,650,000...
Apr 28, 2015

Lipocine Announces Closing of $34.8 Million Common Stock Offering

SALT LAKE CITY, April 29, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the closing of an underwritten public offering of 5,347,500...
Apr 24, 2015

Lipocine Prices $30.2 Million Public Offering of Common Stock

SALT LAKE CITY, April 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has priced an underwritten public offering of 4,650,000...
Apr 23, 2015

Lipocine Announces Proposed Public Offering of Common Stock

SALT LAKE CITY, April 23, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its...
Apr 10, 2015

Lipocine Announces Presentation of Additional LPCN 1021 Clinical Data at American Society of Andrology 40th Annual Conference

SALT LAKE CITY, April 10, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced that additional data from its ongoing Study of Oral Androgen...
Mar 24, 2015

Lipocine Announces Results From Pre-NDA Meeting for LPCN 1021, an Oral Testosterone Product Candidate

SALT LAKE CITY, March 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has completed its pre-New Drug Application ("NDA")...
Mar 11, 2015

Lipocine Announces Financial and Operational Results for the Full Year 2014

SALT LAKE CITY, March 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2014, as...
Mar 4, 2015

Lipocine to Present at the 27th Annual ROTH Conference

SALT LAKE CITY, March 4, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice...
Feb 27, 2015

Lipocine Announces Presentation of LPCN 1021 Clinical Data at ENDO 2015

SALT LAKE CITY, Feb. 27, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from its ongoing Study of Oral Androgen Replacement ("SOAR"
Feb 24, 2015

Lipocine to Present at the Cowen and Company 35th Annual Health Care Conference

SALT LAKE CITY, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and Chief Executive Officer, and...
Jan 30, 2015

Lipocine Announces Presentation of LPCN 1107 Clinical Data at the Society for Maternal-Fetal Medicine 35th Annual Meeting

SALT LAKE CITY, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from a successful Phase 1 study of LPCN 1107, the...
Jan 12, 2015

Lipocine Announces Positive Phase 1b Top-Line Results With LPCN 1107 in Pregnant Women

First demonstration of relevant hydroxyprogesterone caproate levels following oral administration in pregnant women

SALT LAKE CITY, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced successful top-line results of a Phase 1b study of LPCN 1107, the...
Dec 15, 2014

FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021

SALT LAKE CITY, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation from the U.S. Food and Drug...
Nov 25, 2014

Lipocine to Present at the Piper Jaffray 26th Annual Healthcare Conference

SALT LAKE CITY, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice...
Nov 17, 2014

Lipocine Announces Management Changes

SALT LAKE CITY, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced changes to its executive management team. Changes include the...

Show per page

Investor Relations

Press Releases

About

Pipeline

Info

Legal